Natural Product (NP) Details
General Information of the NP (ID: NP3812) | |||||
---|---|---|---|---|---|
Name |
Oxymatrine
|
||||
Synonyms |
Oxymatrine; Ammothamnine; Matrine N-oxide; 16837-52-8; Oxysophoridine; Matrine oxide; Oxymatrine,(S); Matrine 1beta-oxide; 54809-74-4; CHEBI:2672; (7aS,13aR,13bR,13cS)dodecahydro-1H,5H,10H-dipyrido[2,1-f:3',2',1'-ij][1,6]naphthyridin-10-one 4-oxide; MFCD00210339; SMR000543093; Pachycarpidine; Matrine 1-oxide; MLS001215101; MLS006011817; Oxymatrine (Matrine N-oxide); CHEMBL458337; SCHEMBL13394285; DTXSID40937482; HMS2854E03; AMY25589; ZINC3881804; 7967AB; BBL030371; s2338; STK801916; AKOS004120031; AKOS022168212; AC-6063; CCG-267091; NCGC00346596-01; NCGC00346596-02; SOPHORIDINE N-OXIDE/OXYSOPHORIDINE; AS-15173; O357; AB0016411; C10749; W-2361; Q-100202; Q15425294; (4(1)S,7aS,13aR,13bR)-10-oxohexadecahydrodipyrido[2,1-f:3',2',1'-ij][1,6]naphthyridine 4-oxide; 1212383-03-3; 4-Oxotetradecahydro-1H,10H-4lambda~5~-dipyrido[2,1-f:3',2',1'-ij][1,6]naphthyridin-10-one; rel-(41S,7aS,13aR,13bR)-10-Oxohexadecahydrodipyrido[2,1-f:3',2',1'-ij][1,6]naphthyridine 4-oxide
Click to Show/Hide
|
||||
Species Origin | Sophora flavescens ... | Click to Show/Hide | |||
Sophora flavescens | |||||
Disease | Colorectal cancer [ICD-11: 2B91] | Investigative | [1] | ||
Structure |
Click to Download Mol2D MOL |
||||
Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product | |||||
Formula |
C15H24N2O2
|
||||
PubChem CID | |||||
Canonical SMILES |
C1CC2C3CCC[N+]4(C3C(CCC4)CN2C(=O)C1)[O-]
|
||||
InChI |
1S/C15H24N2O2/c18-14-7-1-6-13-12-5-3-9-17(19)8-2-4-11(15(12)17)10-16(13)14/h11-13,15H,1-10H2/t11-,12+,13+,15-,17?/m0/s1
|
||||
InChIKey |
XVPBINOPNYFXID-LHDUFFHYSA-N
|
||||
CAS Number |
CAS 16837-52-8
|
||||
ChEBI ID | |||||
Herb ID | |||||
SymMap ID | |||||
TCMSP ID |
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
---|---|---|---|---|---|---|
α. A List of Drug(s) Whose Efficacy can be Enhanced by This NP | ||||||
Sodium ferulate | Influenza | Click to Show/Hide the Molecular Data of This Drug | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [2] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
Molecule(s)
Regulation |
Down-regulation | Expression | IL19 | Molecule Info |
Pathway MAP
|
|
Down-regulation | Expression | p105 | Molecule Info |
Pathway MAP
|
||
In-vivo Model | Swiss mice (18-20 g) and Sprague-Dawley rats (120-150 g) were used in this study. | |||||
Experimental
Result(s) |
SF and OMT combination had an obvious protective effect on PQ-induced lung injury. The anti-infammatory and antioxidant effect might be involved in the mechanism. |
Target and Pathway | ||||
---|---|---|---|---|
Target(s) | Caspase-3 (CASP3) | Molecule Info | [3] | |
KEGG Pathway | MAPK signaling pathway | Click to Show/Hide | ||
2 | p53 signaling pathway | |||
3 | Apoptosis | |||
4 | Natural killer cell mediated cytotoxicity | |||
5 | TNF signaling pathway | |||
6 | Serotonergic synapse | |||
7 | Non-alcoholic fatty liver disease (NAFLD) | |||
8 | Alzheimer's disease | |||
9 | Parkinson's disease | |||
10 | Amyotrophic lateral sclerosis (ALS) | |||
11 | Huntington's disease | |||
12 | Epithelial cell signaling in Helicobacter pylori infection | |||
13 | Pertussis | |||
14 | Legionellosis | |||
15 | Toxoplasmosis | |||
16 | Amoebiasis | |||
17 | Tuberculosis | |||
18 | Hepatitis B | |||
19 | Herpes simplex infection | |||
20 | Pathways in cancer | |||
21 | Viral carcinogenesis | |||
22 | Proteoglycans in cancer | |||
23 | MicroRNAs in cancer | |||
24 | Colorectal cancer | |||
25 | Viral myocarditis | |||
NetPath Pathway | TCR Signaling Pathway | Click to Show/Hide | ||
2 | IL2 Signaling Pathway | |||
3 | IL4 Signaling Pathway | |||
Panther Pathway | Apoptosis signaling pathway | Click to Show/Hide | ||
2 | FAS signaling pathway | |||
3 | Huntington disease | |||
4 | CCKR signaling map ST | |||
Pathway Interaction Database | LPA receptor mediated events | Click to Show/Hide | ||
2 | Calcineurin-regulated NFAT-dependent transcription in lymphocytes | |||
3 | FAS (CD95) signaling pathway | |||
4 | Role of Calcineurin-dependent NFAT signaling in lymphocytes | |||
5 | Posttranslational regulation of adherens junction stability and dissassembly | |||
6 | p75(NTR)-mediated signaling | |||
7 | HIV-1 Nef: Negative effector of Fas and TNF-alpha | |||
8 | Caspase Cascade in Apoptosis | |||
9 | Syndecan-2-mediated signaling events | |||
Reactome | SMAC binds to IAPs | Click to Show/Hide | ||
2 | SMAC-mediated dissociation of IAP:caspase complexes | |||
3 | Apoptotic cleavage of cellular proteins | |||
4 | Degradation of the extracellular matrix | |||
5 | NADE modulates death signalling | |||
6 | Activation of DNA fragmentation factor | |||
7 | Caspase-mediated cleavage of cytoskeletal proteins | |||
WikiPathways | DNA Damage Response | Click to Show/Hide | ||
2 | SIDS Susceptibility Pathways | |||
3 | Apoptosis Modulation by HSP70 | |||
4 | MAPK Signaling Pathway | |||
5 | Copper homeostasis | |||
6 | FAS pathway and Stress induction of HSP regulation | |||
7 | Signaling by Hippo | |||
8 | Apoptosis | |||
9 | Amyotrophic lateral sclerosis (ALS) | |||
10 | Spinal Cord Injury | |||
11 | BDNF signaling pathway | |||
12 | Integrated Pancreatic Cancer Pathway | |||
13 | Oncostatin M Signaling Pathway | |||
14 | Parkinsons Disease Pathway | |||
15 | Corticotropin-releasing hormone | |||
16 | Allograft Rejection | |||
17 | AGE/RAGE pathway | |||
18 | TNF alpha Signaling Pathway | |||
19 | Prostate Cancer | |||
20 | Alzheimers Disease | |||
21 | TWEAK Signaling Pathway | |||
22 | Integrated Breast Cancer Pathway | |||
23 | Signalling by NGF | |||
24 | Integrated Cancer pathway | |||
25 | Regulation of Apoptosis | |||
26 | Intrinsic Pathway for Apoptosis | |||
27 | Apoptotic execution phase | |||
28 | Apoptosis Modulation and Signaling | |||
29 | miRNA Regulation of DNA Damage Response |